Navigation Links
Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
Date:1/28/2008

ne health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both bone building and anti-bone loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize these compounds. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
2. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
3. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
4. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
5. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
6. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
7. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
8. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
9. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
10. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... Industry Analysis, Size, Share, Growth, Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is a ... RNA) into cells. This technology helps the cells to ... metabolism by affecting the nuclear genes. The transfection technology ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... 2014 Understanding the need for better ... and the gap that currently exists in this area, ... industry-leading portfolio of validated ion channel and GPCR cell ... lines, as ion channels control many critical physiological functions ... creates the potential to treat a variety of human ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Fla., Dec. 6, 2010 Investigators report no evidence of ... in a gene therapy trial using a vector under development ... (University College London) to correct the inherited bleeding disorder. ... test, with low and intermediate doses of the vector expected ...
... 6, 2010 See video from Novartis at: ... Novartis announced 24-month data showing that Tasigna® (nilotinib) ... of adult patients with newly diagnosed Philadelphia chromosome-positive ... These new data, from the first Phase III ...
... Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: ... follow up results from the Company,s pivotal phase III ... Company,s recent Marketing Authorization Application (the "MAA") currently under ... The end-of-study results showed continued improvement in the trial,s ...
Cached Biology Technology:Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 2Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 3Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 2New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 3New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 5New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 6
(Date:7/10/2014)... -- Smart technology emphasis grows in biometrics sector ... NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: AAPL ), Visa Inc. (NYSE: ... (OTCQB: NXTD) a biometric authentication company focused on the growing ... of 30 second spots on CNBC for its next generation ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... According to the new market ... Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application ... & Finance), and Geography - Global Trends & Forecasts ... Fingerprint Sensors Market is projected to cross $14.35 Billion ... from 2014 to 2020. Browse more than ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... with atrial fibrillation are often treated with anticoagulants to ... dose and patients have to have their blood tested ... of Gothenburg and Chalmers University of Technology have now ... risk assessments. Atrial fibrillation, or irregular heartbeat, ...
... day of competition in London, a team of four ... emerged as the winners of this year,s Biotechnology Young ... Biotechnology Young Entrepreneurs Scheme (YES) competition are Ben Owens, ... University of Oxford. The team pitched their ...
... industry is booming more and more solar modules ... plants are increasingly feeding power into the grid. Multi-junction ... can achieve efficiencies of up to 43 percent - ... crystalline silicon. The trick: they consist of several semi-conductor ...
Cached Biology News:New method for safer dosing of anticoagulants 2Winning early-career researchers excel in entrepreneurship 2Winning early-career researchers excel in entrepreneurship 3Fraunhofer researchers receive the Franco-German Business Award 2011 2
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
...
Biology Products: